Key Stats for e.l.f. Stock
- Past-Week Performance: -11%
- 52-Week Range: $49.4 to $151
- Current Price: $74.7
What Happened?
Shares of e.l.f. Beauty (ELF), a mass-market cosmetics and skin care company built on premium-quality products at accessible price points, fell 11% over the past week as its forward price-to-earnings multiple compressed from roughly 30x three months ago to 19.84x, reflecting a market reckoning with slowing organic growth and mounting legal scrutiny.
Two shareholder law firms, Halper Sadeh and Kahn Swick & Foti, opened separate investigations by March 13 into whether ELF’s officers and directors overstated revenue, misrepresented inventory trends, and breached fiduciary duties to shareholders, piling onto a stock already down 39% in calendar 2025 despite Q3 sales rising 38% to $489.5 million, above analysts’ estimate of $460.2 million.
Rhode, the skin care brand founded by Hailey Bieber that ELF acquired in August, contributed $128 million to Q3 net sales and accounted for roughly 36 of the 38% points of headline revenue growth, exposing an organic business growing at only approximately 2% year-over-year excluding the acquisition.
Chairman and CEO Tarang Amin stated on the Q3 FY2026 earnings call that “we’re one of only six public consumer companies out of 546 that has grown for 28 straight quarters and average at least 20% sales growth per quarter,” yet CFO Mandy Fields confirmed global consumption growth had slowed to approximately 6% from the 8% assumed in November 2025 guidance.
ELF’s $400 million remaining buyback authorization, Rhode’s annualized net sales run-rate of approximately $360 million growing at 70% year-over-year, and a Spring 2026 retail expansion into Walmart for Naturium and DM Germany for e.l.f. Cosmetics position the company for a potential re-rating, though the organic growth gap and unresolved legal investigations remain the market’s primary overhang.
Wall Street’s Take on ELF Stock
The multiple compression from roughly 30x to 19.84x forward earnings has created a rare disconnect for a company whose EBITDA margin holds at approximately 20% and whose FY2026 consensus revenue estimate of $1.61 billion implies 22.8% growth even in a slowing organic environment.
Rhode’s $128 million Q3 contribution — driving 36 of the headline 38 percentage points of growth — justifies the TIKR model’s mid-case revenue CAGR assumption of 13.5% through FY2030, given Rhode’s annualized run-rate of approximately $360 million growing at 70% year-over-year with less than 20% of global Sephora doors currently carrying the brand.
ELF’s EBITDA margin holds at approximately 20% through 2026E and expands to 20.8% by 2027E, against Estee Lauder’s 13.8% EBITDA margin in 2025 contracting from 22.9% in 2021, making ELF the structurally stronger compounder at the cheaper price.
Fourteen of 17 analysts covering ELF rate it buy or outperform, with a mean price target of $112.79 against a current price of $74.66, implying approximately 51% upside as the Street anticipates organic consumption stabilizing and Rhode’s international rollout accelerating distribution gains.
The $85 low target anchors the bear case to sustained organic deceleration and unresolved legal pressure from Halper Sadeh and Kahn Swick, while the $136.00 high target reflects full execution on Rhode’s global Sephora expansion and a return of e.l.f. Cosmetics U.S. consumption growth above 8%.
What Does the Valuation Model Say?
The TIKR mid-case target of $126.60, implying a 14% annualized IRR through March 2030, rests on a 13.5% revenue CAGR assumption supported by Rhode’s record-breaking Sephora launches across North America, the U.K., and Australia alongside Naturium’s first Walmart entry in Spring 2026.
The market is pricing ELF as though organic growth is broken, but 28 consecutive quarters of net sales growth and 800 bps of color cosmetics share gained over five years contradict that read at 19.84x forward earnings.
Rhode’s annualized $360 million run-rate, a $400 million buyback authorization, and Naturium’s Walmart launch in Spring 2026 together support the TIKR $126.60 target if consumption stabilizes at 6% globally.
Management’s February 4 confirmation that 75% of the portfolio sits at $10 or below signals the value proposition that drove organic outperformance remains structurally intact despite the Q2 miss and legal scrutiny.
Free cash flow turns deeply negative at roughly negative $220 million in FY2026E as Rhode integration costs peak, and any deterioration in Rhode’s sell-through at Sephora would invalidate the TIKR model’s 13.5% revenue CAGR assumption directly.
Q4 FY2026 earnings in May 2026 is the confirmation event — watch for organic consumption exiting the 6% global rate and Rhode’s Q4 net sales contribution relative to the $260 million to $265 million full-year guidance.
Should You Invest in e.l.f. Beauty, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ELF stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track e.l.f. Beauty, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ELF stock on TIKR for Free →
